JPRN-UMIN000039784已完成未知
ivolumab plus Ipilimumab versus existing immunotherapies in patients with PD-L1-positive advanced non-small cell lung cancer: a systematic review and network meta-analysis. - Nivolumab plus Ipilimumab for PD-L1-positive advanced non-small cell lung cancer
Showa University School of Medicine0 个研究点目标入组 4,011 人开始时间: 2020年3月14日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 4,011
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Others,meta-analysis etc
入排标准
- 年龄范围
- 18years-old 至 100years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients with EGFR-sensitive mutations wereexcluded in the case of histologically squamous cell carcinoma.
研究者
相似试验
进行中（未招募）
1 期
Ipilimumab in combination with Nivolumab followed by Nivolumab monotherapy in patients with unresectable or oligometastatic melanoma.Patients with histologically or cytologically confirmed AJCC (8th ed.) Stage IIIB -IV resectable melanoma.MedDRA version: 21.1Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 100000004864EUCTR2018-002172-40-ITISTITUTO EUROPEO DI ONCOLOGIA35
已完成
不适用
ImmunoModulation by the Combination of Ipilimumab and nivolumab neoadjuvant to Surgery In advanced Or recurrent Head and Neck Carcinoma, (IMCISION), a phase-Ib/II trial. Subtitle: Hypoxia as a determinant for the effect of nivolumab with or without ipilimumab on intra-tumoral T cell capacityNL-OMON42832Antoni van Leeuwenhoek Ziekenhuis32
进行中（未招募）
1 期
ivolumab and ipilimumab +/- UV1 vaccination as second line treatment in patients with malignant mesothelioma (the NIPU-study)Malignant pleural mesothelioma (MPM)MedDRA version: 20.0Level: PTClassification code 10059518Term: Pleural mesothelioma malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-002721-30-DKOslo University Hospital118
进行中（未招募）
1 期
ivolumab and ipilimumab +/- UV1 vaccination as second line treatment in patients with malignant mesothelioma (the NIPU-study)EUCTR2019-002721-30-ESOslo University Hospital118
进行中（未招募）
1 期
ivolumab and ipilimumab +/- UV1 vaccination as second line treatment in patients with malignant mesothelioma (the NIPU-study)Malignant pleural mesothelioma (MPM)MedDRA version: 20.0Level: PTClassification code: 10059518Term: Pleural mesothelioma malignant Class: 100000004864CTIS2022-502604-67-00Oslo University Hospital Hf118